secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2024-12-04T23:59:59+00:00
Accession:  0001628280-24-049951
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex obtains waiver of ~$3.5M in accrued royalties from Dartmouth contingent on appeal bond in Elysium case
--------------------------------------------------------------------------------

- Dartmouth waives ~$3.5M in accrued unpaid royalties, license fees, and maintenance expenses under exclusive license agreements.
- Waiver contingent on ChromaDex securing an Appeal Bond for fee judgment in Delaware patent infringement case against Elysium Health.
- ChromaDex executed the Appeal Bond as of December 3, 2024; plans to move to stay execution of fee judgment pending appeal.
- No further royalties or payments will be owed to Dartmouth for the licensed patents after effective date of Supplemental Agreement.
- Supplemental Agreement supplements prior exclusive license agreements from 2012 and 2014 for Dartmouth-owned U.S. patents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024049951/0001628280-24-049951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024049951/cdxc-20241204.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-049951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer